Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2014. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMR) under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
Key transaction details include:
- Transaction Date: October 14, 2014
- Event: Notional re-investment of dividends paid on October 2, 2014.
- Share Price: 1,404.00 pence per Ordinary Share; $45.63 per American Depositary Share (ADS).
Material Changes
The filing reports increases in notional interests in Ordinary Shares and ADSs for various Directors and PDMRs. No material changes to the company's financial position or operations are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of share plan activity.
Important Facts for Investors
- The filing confirms the re-investment of dividends into the 2009 Performance Share Plan for named executives.
- Notional dividends will be paid out based on the percentage of holdings that vest after the relevant measurement period.
- The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
- Specific increases in notional shares were recorded for Sir Andrew Witty (18,700.225 Ordinary Shares) and other listed directors.